Table 1. Risk factors and screening results in the subgroup with SNP data.
| Variable | Baseline Abnormal TVU | Incident Abnormal TVU | Other TVU | Baseline vs. Incident/Otherx2 p-value | Baseline/Incident vs. Otherx2 p-value |
| Age at entry | |||||
| 55–59 | 12 (24.0) | 7 (15.2) | 246 (24.4) | ||
| 60–64 | 15 (30.0) | 13 (28.3) | 321 (31.8) | ||
| 65–69 | 14 (28.0) | 14 (30.4) | 280 (27.7) | ||
| 70+ | 9 (18.0) | 12 (26.1) | 163 (16.1) | 0.99 | 0.43 |
| Total | 50 | 46 | 1010 | ||
| Race | |||||
| Caucasian | 43 (86.0) | 37 (80.4) | 912 (90.3) | ||
| Non-Caucasian | 7 (14.0) | 9 (19.6) | 98 (9.7) | 0.38 | 0.03 |
| Total | 50 | 46 | 1010 | ||
| Nulliparous | |||||
| No | 45 (90.0) | 42 (91.3) | 912 (90.4) | ||
| Yes | 5 (10.0) | 4 (8.7) | 97 (9.6) | 0.92 | 0.94 |
| Total | 50 | 46 | 1009 | ||
| Family hx breast cancer | |||||
| No | 44 (88.0) | 36 (78.3) | 850 (84.6) | ||
| Yes, female relative | 6 (12.0) | 8 (17.4) | 138 (13.7) | ||
| Yes, male relative | 0 | 1 (2.2) | 2 (0.2) | ||
| Possibly | 0 | 1 (2.2) | 15 (1.5) | 0.78 | 0.48 |
| Total | 50 | 46 | 1005 | ||
| Family hx ovarian cancer | |||||
| No | 47 (94.0) | 41 (89.1) | 949 (94.4) | ||
| Yes, immediate family | 3 (6.0) | 3 (6.5) | 40 (4.0) | ||
| Possibly | 0 | 2 (4.4) | 16 (1.6) | 0.53 | 0.53 |
| Total | 50 | 46 | 1005 | ||
| PMH use | |||||
| Ever | 33 (66.0) | 30 (65.2) | 617 (61.1) | ||
| Never | 17 (34.0) | 16 (34.8) | 388 (38.5) | ||
| Unknown | 0 | 0 | 4 (0.4) | 0.74 | 0.59 |
| Total | 50 | 46 | 1009 | ||
| OC use | |||||
| Never | 23 (46.0) | 26 (56.5) | 511 (50.7) | ||
| Ever | 27 (54.0) | 20 (43.5) | 496 (49.3) | 0.49 | 0.96 |
| Total | 50 | 46 | 1007 | ||
| Smoker | |||||
| Never | 13 (26.0) | 13 (28.3) | 324 (32.1) | ||
| Current | 15 (30.0) | 16 (34.8) | 310 (30.7) | ||
| Former | 22 (44.0) | 17 (37.0) | 376 (37.2) | 0.57 | 0.6 |
| Total | 50 | 46 | 1010 | ||
| Benign cyst or tumor | |||||
| No | 35 (79.5) | 37 (84.1) | 867 (90.4) | ||
| Yes | 9 (20.5) | 7 (15.9) | 92 (9.6) | 0.02 | 0.01 |
| Total | 44 | 44 | 959 | ||
| Age of first menstrual period | |||||
| <10 | 0 | 0 | 12 (1.2) | ||
| 10–11 | 8 (16.0) | 12 (26.1) | 167 (16.6) | ||
| 12–13 | 27 (54.0) | 27 (58.7) | 572 (56.8) | ||
| 14–15 | 12 (24.0) | 5 (10.9) | 215 (21.4) | ||
| 16+ | 3 (6.0) | 2 (4.4) | 41 (4.1) | 0.86 | 0.57 |
| Total | 50 | 46 | 1007 | ||
| GWAS case/control | |||||
| Control | 22 (44.0) | 26 (56.5) | 520 (51.5) | ||
| Case | 28 (56.0) | 20 (43.5) | 490 (48.5) | 0.29 | 0.78 |
| Bladder | 4 | 6 | 84 | ||
| Breast | 4 | 1 | 32 | ||
| Colon | 4 | 1 | 79 | ||
| Lung | 14 | 9 | 249 | ||
| Pancreas | 2 | 3 | 46 | ||
| Total | 50 | 46 | 1010 |
TVU = transvaginal ultrasound; Family hx = family history; PMH = Post-menopausal hormone; OC = oral contraceptive; GWAS = genome-wide association study.